Basel Metropolitan Area
I am a highly motivated and solution-oriented person with extensive working experience in biopharmaceutical development. As a team player, I thrive in multidisciplinary assignments and proactively communicate with my co-workers to tackle challenging tasks with a “can-do” mindset.
• Tactical and technical resource planning for both DP Science groups • Partnering with group heads for strategic assignment of entire project teams (portfolio-driven, development-driven, or tactical outsourcing) • Accountable for quality of technical operations within DPD (enabling operational excellence, capabilities mapping, scientific knowledge build up and maintenance) • Facilitation of internal and external stakeholder alignment for Bx DPD • Optimize and sustain continuous improvement for Bx DPD Basel • SPoC for specific business critical interfaces • Coaching of peers and students
Functional Lead in the Biologics Drug Product Development unit: • Designing, leading, performing, and coordinating unit operations covering early and late phase drug product development as well as tech transfers leading to BLA submissions as a Drug Product Functional Lead (FL) • Core member and/or leader of several interdisciplinary teams/networks representing Bx Drug Product Development Basel (e.g. DP subteams, several technical networks, RCIs, extended Leadership Team, FL role workstream) • Author/reviewer/approver of CMC relevant documents • Managing and optimizing collaborations with internal and external stakeholders (different internal interfaces, CROs and CMOs) • Leading initiative to drive knowledge maintenance & transfer within the unit • Initiator and co leader of the Bx Early Talent Program for postgraduates as well as mentor for the patricipants
• Co-leader in a safety project on in vivo biodistribution of nanomaterials • Optimizing nanomedicine testing strategies with EMPA and SCAHT • Validation of a novel pre-clinical hazard evaluation guideline for nanomedicines
PhD thesis title: Assessing the safety of engineered nanoparticles for therapeutic use • Conducting nanotoxicology/nanosafety studies in vitro and in vivo in collaboration with (inter)national academic partners and authorities (e.g. NanoReg2, EMPA, SCAHT, BAG) • Designing, planning, performing, and evaluating assays and testing strategies in a multidisciplinary environment • Writing scientific publications and proposals as well as presenting scientific results at (inter)national meetings and conferences • Leading graduate courses on semi-solid dosage forms • Supervision of two master theses and one PhD candidate
• Studying the toxic potential of antiarrythmic active agents and their metabolites when interacting with the human ether-a-go-go related gene (hERG) by the use of in silico methods • Method validation and pinpointing of molecular characteristics in active agents and their metabolites increasing the toxic potential towards hERG
• Analytical testing of oral dosage forms under GMP conditions • Translation of equipment specific SOPs from German to English